Study reaffirms the Foundation’s commitment to advance solutions to the growing challenge of antibiotic resistance
Site Search
The Cystic Fibrosis Foundation awarded up to $4.7 million to EnBiotix Inc. to study the potential use of inhaled colistin as an additional option to treat Pseudomonas infections in people with cystic fibrosis who are not responding to current treatments.
Investment will support discovery research of a novel Gene CodingTM approach that could benefit all people with CF regardless of their mutation
The Cystic Fibrosis Foundation awarded up to $3.5 million to Arrevus Inc. to test a potential treatment for pulmonary exacerbations in people with cystic fibrosis in a late phase clinical trial.
Breadth of expertise in business, philanthropy, community engagement, and venture capital to help advance Foundation’s mission
Groups urging need for revitalizing antimicrobial development call for passage of the bill this year
The Foundation, in collaboration with external community advisors, finalizes recommendations in area of Community to help foster more inclusion and improve the experiences of Black people living with and impacted by cystic fibrosis.
A transformative leader for more than two decades, Marshall will transition to advisory role
Ad hoc patient advocacy coalition provides comments to Pennsylvania’s Insurance Commission to inform decision making regarding the state’s essential health benefits benchmark plan.
The CF Foundation writes to Michigan’s House Committee on Insurance and Financial Services to provide comments on SB 483: The Prescription Drug Cost and Affordability Review Act, which would create a prescription drug affordability board in the state.